Fennec Pharma(FENC) - 2024 Q4 - Annual Results

Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40$7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has$26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ PEDMARQ ...